Abstract
There has been an explosion of our knowledge in cytokine biology in the last decade. Such knowledge is being quickly translated into the identification of etiologies and improved prophylaxis and therapy of disease. While cytokines have the potential to be used as therapeutics or immune adjuvants for certain diseases, they may also be culprits as therapeutic targets in other diseases. This review article serves as an introduction to the other five articles in this thematic issue each of which has a specific focus on the frontier of cytokine therapeutic biology. This review contains sections dealing with general cytokine properties, cytokine classifications, human conditions caused by cytokine under-expression and over-expression, Th1 and Th2 paradigm, cytokine therapy for acute/chronic inflammatory conditions, cytokine therapy for infectious diseases, and cytokine therapy for cancer.
Keywords: Cytokines, Therapeutics Agnets, Prophylaxis, Th1, Th2, paradigm, therapy, Inflammatory, Infectious diseases, Recombinant, Immune, prophylactic vaccines, autoimmune, cancer, transgene, receptors, Chronic, Wound Healing, GM CSF, Fibrotic, Bronchial Asthma, Rheumatoid Arthritis
Current Pharmaceutical Design
Title: Consideration of Cytokines as Therapeutics Agents or Targets
Volume: 6 Issue: 6
Author(s): Zhou Xing and Jun Wang
Affiliation:
Keywords: Cytokines, Therapeutics Agnets, Prophylaxis, Th1, Th2, paradigm, therapy, Inflammatory, Infectious diseases, Recombinant, Immune, prophylactic vaccines, autoimmune, cancer, transgene, receptors, Chronic, Wound Healing, GM CSF, Fibrotic, Bronchial Asthma, Rheumatoid Arthritis
Abstract: There has been an explosion of our knowledge in cytokine biology in the last decade. Such knowledge is being quickly translated into the identification of etiologies and improved prophylaxis and therapy of disease. While cytokines have the potential to be used as therapeutics or immune adjuvants for certain diseases, they may also be culprits as therapeutic targets in other diseases. This review article serves as an introduction to the other five articles in this thematic issue each of which has a specific focus on the frontier of cytokine therapeutic biology. This review contains sections dealing with general cytokine properties, cytokine classifications, human conditions caused by cytokine under-expression and over-expression, Th1 and Th2 paradigm, cytokine therapy for acute/chronic inflammatory conditions, cytokine therapy for infectious diseases, and cytokine therapy for cancer.
Export Options
About this article
Cite this article as:
Xing Zhou and Wang Jun, Consideration of Cytokines as Therapeutics Agents or Targets, Current Pharmaceutical Design 2000; 6 (6) . https://dx.doi.org/10.2174/1381612003400623
DOI https://dx.doi.org/10.2174/1381612003400623 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Survival and Immunosuppression Induced by Hepatocyte Growth Factor in Chronic Lymphocytic Leukemia
Current Molecular Medicine Editorial [Hot Topic: Modulators of the Innate Immune Response (Guest Editor: Suzanne S. Bohlson)]
Current Drug Targets Establishing Genomic/Transcriptomic Links Between Alzheimer’s Disease and Type 2 Diabetes Mellitus by Meta-Analysis Approach
CNS & Neurological Disorders - Drug Targets Medical Treatment of Hirsutism in Women
Current Medicinal Chemistry Editorial [Hot Topic: Latest Developments in Pharmaceutical Design of Arachidonic Acid Metabolites: Prostaglandins, Thromboxanes, Hepoxilins and Isoprostanes (Executive Editors: J.-M. Dogne and K.-H. Ruan )]
Current Pharmaceutical Design Substance P at the Neuro-Immune Crosstalk in the Modulation of Inflammation, Asthma and Antimicrobial Host Defense
Inflammation & Allergy - Drug Targets (Discontinued) Antiphospholipid Syndrome: Characteristics and Obstetrical Management
Current Drug Targets Lactoferrin Derived Peptides: Mechanisms of Action and their Perspectives as Antimicrobial and Antitumoral Agents
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic: “Supramolecular Transmembrane Nanocarriers for Targeted Therapeutics” (Guest Editor: Grzegorz Bazylak) ]
Current Drug Discovery Technologies The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases
Current Medicinal Chemistry Adiponectin and its Role in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets A Molecular Understanding of Mast Cell Activation and the Promise of Anti- Allergic Therapeutics
Current Medicinal Chemistry Nanoparticulate Drug Delivery to Colorectal Cancer: Formulation Strategies and Surface Engineering
Current Pharmaceutical Design Should We be Concerned About the Inflammatory Response to Endovascular Procedures?
Current Vascular Pharmacology Peripheral Opioid Analgesia
Current Pharmaceutical Biotechnology Therapeutic Potential of Janus Kinase 3 (JAK3) Inhibitors
Current Pharmaceutical Design Recent Advances in Adenovirus-mediated Gene Therapy for Cerebral Ischemia
Current Gene Therapy Pharmacological Uses of the Plants Belonging to the Genus <i>Commiphora</i>
Cardiovascular & Hematological Agents in Medicinal Chemistry Recent Patents Therapeutic Agents for Cancer
Recent Patents on Anti-Cancer Drug Discovery Novel Insights into Biased Agonism at G Protein-Coupled Receptors and their Potential for Drug Design
Current Pharmaceutical Design